Posts

Lennox-Gastaut Syndrome (LGS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Lennox-Gastaut Syndrome (LGS) Emerging Therapy and TPP Insights Thelansis’s “Lennox-Gastaut Syndrome (LGS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Lennox-Gastaut Syndrome (LGS) Overview Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset epilepsy syndrome marked by multiple seizure types and significant cognitive and behavioral impairment, arising from a wide range of underlying causes rather than a single genetic origin, which has long complicated efforts to build a unified treatment approach. Care today relies on adjunctive anti-seizure medications alongside surgical and device-based options such as nerve stimulation and corpus callosotomy, yet complete seizure freedom remains the exception, and the syndrome’s broader t...
Post a Comment
Read more

Lyme Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Lyme Disease Emerging Therapy and TPP Insights Thelansis’s “Lyme Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Lyme Disease Overview Lyme disease is a tick-borne bacterial infection that, when caught early, is generally treated successfully with a short course of oral antibiotics, making acute care for typical presentations a largely solved clinical problem. The more persistent challenge lies at two edges of that success: a meaningful minority of patients continue to experience fatigue, joint pain, or cognitive symptoms even after standard antibiotic treatment; a poorly understood condition that has resisted consensus diagnosis and effective therapy, and prevention has lacked a viable tool since an earlier vaccine was withdraw...
Post a Comment
Read more

Lipodystrophy Syndromes – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Lipodystrophy Syndromes Emerging Therapy and TPP Insights Thelansis’s “Lipodystrophy Syndromes Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Lipodystrophy Syndromes Overview Lipodystrophy syndromes are a heterogeneous group of rare disorders characterized by a selective loss of adipose tissue, driving severe metabolic complications like profound insulin resistance, hypertriglyceridemia, hepatic steatosis, and secondary diabetes. Classified as congenital or acquired, these syndromes span generalized and partial phenotypes of varying clinical severity. Endogenous leptin deficiency drives the underlying metabolic collapse, positioning the recombinant human leptin analog metreleptin as the foundational cornerstone therapy for generalized ...
Post a Comment
Read more

Dravet Syndrome (DS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Dravet Syndrome (DS) Emerging Therapy and TPP Insights Thelansis’s “Dravet Syndrome (DS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Dravet Syndrome (DS) Overview Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare and refractory genetic epilepsy that typically begins in the first year of life. The disorder is primarily characterized by frequent, prolonged seizures often triggered by hyperthermia, such as fevers or warm baths, and eventually progresses to include multiple seizure types including myoclonic and atypical absence seizures. Approximately 80 to 85 percent of cases result from a mutation or deletion in the SCN1A gene, which encodes the Nav1.1 voltage-gated sodium channel essential ...
Post a Comment
Read more

Cutaneous T-cell Lymphoma (CTCL) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Cutaneous T-cell Lymphoma (CTCL) Emerging Therapy and TPP Insights Thelansis’s “Cutaneous T-cell Lymphoma (CTCL) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Cutaneous T-cell Lymphoma (CTCL) Overview Cutaneous T-cell lymphoma (CTCL) is a rare, skin-based blood cancer in which malignant T-cells infiltrate the skin, typically progressing slowly from patches and plaques toward more advanced tumor or blood-involved stages, with mycosis fungoides as the common form and Sézary syndrome its more aggressive counterpart. Treatment has long followed a stepwise approach, starting with skin-directed therapies such as topical agents, light-based treatment, and localized radiation, then escalating to systemic options, including anti...
Post a Comment
Read more

Epilepsy – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Epilepsy Emerging Therapy and TPP Insights Thelansis’s “Epilepsy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Epilepsy Overview Epilepsy is a chronic neurological condition marked by recurrent seizures, and while a broad set of anti-seizure medications has long formed the backbone of treatment, a persistent share of patients continue to experience seizures despite multiple drug options, a category known as drug-resistant epilepsy that remains one of neurology’s most durable unmet needs. For these patients, care has traditionally escalated toward surgical removal of the seizure-generating brain region or implantable neuromodulation devices that interrupt abnormal electrical activity, alongside dietary approaches in sele...
Post a Comment
Read more

Cutaneous Squamous Cell Carcinoma (cSCC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Cutaneous Squamous Cell Carcinoma (cSCC) Emerging Therapy and TPP Insights Thelansis’s “Cutaneous Squamous Cell Carcinoma (cSCC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Cutaneous Squamous Cell Carcinoma (cSCC) Overview Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer that is usually curable with surgery when caught early, but a meaningful subset of cases become locally advanced, recurrent, or metastatic, at which point outcomes historically worsened sharply and treatment options were limited. That calculus changed with the arrival of PD-1 checkpoint immunotherapy, which delivered durable disease control for patients whose cancer could no longer be managed surgically and quickly became the establish...
Post a Comment
Read more